![]() | |
Identifiers | |
---|---|
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
Chemical and physical data | |
Formula | C48H48F2N10O5 |
Molar mass | 882.974 g·mol−1 |
3D model ( JSmol) | |
| |
|
Orforglipron (LY-3502970) is an oral, non-peptide, small molecule glucagon-like peptide-1 receptor agonist developed as a weight loss drug by Eli Lilly and Company. [1] [2] It is easier to produce than current peptide GLP-1 agonists and is expected to be cheaper. [3]
![]() | |
Identifiers | |
---|---|
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
Chemical and physical data | |
Formula | C48H48F2N10O5 |
Molar mass | 882.974 g·mol−1 |
3D model ( JSmol) | |
| |
|
Orforglipron (LY-3502970) is an oral, non-peptide, small molecule glucagon-like peptide-1 receptor agonist developed as a weight loss drug by Eli Lilly and Company. [1] [2] It is easier to produce than current peptide GLP-1 agonists and is expected to be cheaper. [3]